Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954228 | 0.81 | — | — | |
| SCHEMBL2941786 | 0.79 | KMT2A (0.39) | KMT2AMEN1ALDH1A1DPP4KDM4E | |
| SCHEMBL368598 | 0.78 | ALDH1A1 (0.34) | KMT2AMEN1ALDH1A1DPP4KDM4E | |
| SCHEMBL3946398 | 0.76 | MEN1 (0.33) | KMT2AMEN1DPP4 | |
| SCHEMBL2721038 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL4663815 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL21403663 | 0.73 | LMNA (0.33) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL18148922 | 0.73 | KMT2A (0.35) | KMT2AMEN1ALDH1A1DPP4KDM4E | |
| SCHEMBL22283207 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9509560 | 0.71 | MEN1 (0.33) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | KMT2A 3612/4885MEN1 4571/4885ALDH1A1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.